n February 2020, Huang et al.2 published the first report describing the use of non-contrast chest CT in 41 patients with confirmed COVID-19. Since then, the scientific evidence on COVID-19 has been rapidly growing and the clinical indications for chest CT are continuously evolving. Although reverse transcription polymerase chain reaction (RT-PCR) is the required laboratory test to confirm the diagnosis of COVID-19, non-contrast chest CT may represent a valid tool in the initial assessment of this patient population. Nevertheless, currently there is no consensus on its role within the major Professional Scientific Societies. For example, in China, during the early phase of the outbreak, CT was widely used as a supporting tool in the diagnosis of COVID-19.3 However, current guidelines from China's National Health Commission do not include imaging findings in the diagnostic criteria.<br />Likewise, in the last update released on March 22, 2020, the American College of Radiology did not recommend chest CT as a first line imaging modality to screen for COVID-19 pneumonia. Recommendations advised the use of CT imaging in hospitalized, symptomatic patients with specific clinical conditions such as pulmonary embolism, empyema and co-infection.5 However, in a recent statement, the Fleischner Society identified three main scenarios where imaging may be used as a primary diagnostic tool: (1) patients with mild respiratory features consistent with COVID-19 but with risk factors for disease progression, (2) patients with moderate to severe features of COVID-19, regardless of RT-PCR test results, and (3) patients presenting with moderate-to-severe symptoms within a high prevalence of disease environment and with limited testing resources.